Lyell Immunopharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lyell Immunopharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $61.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $130.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $84.68M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $10.65M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.76M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $657.0K | Mar 29, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($274.45M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($342.99M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($234.63M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($183.12M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($250.22M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($204.47M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($129.38M) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($269.40M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($358.76M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($247.01M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($187.06M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($214.78M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($211.94M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($102.09M) | Mar 29, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.05M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $490.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $750.03M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $937.56M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $908.28M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.85M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $108.04M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $95.08M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $104.31M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $197.62M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $189.84M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $248.20M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $382.82M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $654.95M | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $833.25M | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $929.79M | Mar 11, 2025 |
| FY2023 | Dec 31, 2020 | ($292.53M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | ($111.11M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $850.0K | Mar 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (26) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (18) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (15) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (24) | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (26) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (18) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (15) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (24) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.18M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $105.60M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $145.65M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $123.55M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $293.83M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $140.41M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $96.67M | Mar 29, 2022 |